Efterpi Pavlidou Pavlidou

Prof. Dr. Efterpi Pavlidou Pavlidou

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2013 in Epilepsia
Verified
Journal Article
Open access
PDF file
EPEfterpi Pavlidou Pavlidou
Efterpi Pavlidou Pavlidou
CPChristos Panteliadis
Christos Panteliadis
Summary: Objective: Epilepsy following febrile seizures (FS) has been estimated between 2% and 7%. It concerns a prospective study in a large sample of children with a long‐term follow‐up. The aim of this study is to identify the prognostic factors that can lead children with FS to epilepsy.Methods: Children with a first episode of FS were included. We gathered information about prenatal and perinatal history, family history of FS and epilepsy in first‐ and second degree relatives, age at the time of the initial FS, dates of FS recurrences, focality, duration of the FS and recurrent episodes within the same febrile illness, height and duration of fever prior to the seizure, cause of the fever, and frequency of febrile illnesses. Patients were seen every 4–6 months and also at each recurrence.Key Findings: A group of 560 children with a first FS met all entry criteria. Epilepsy was recorded at 5.4%. Statistical analysis was performed between children with epilepsy and those with no afebrile seizure. We analyzed FS recurrences in accordance with the occurrence of epilepsy. From the third FS recurrence and beyond, only focality continued to have prognostic value.Significance: Main prognostic factors for the development of epilepsy after FS are: (1) complex FS that increased the risk for epilepsy 3.6 times, (2) age at onset of FS beyond the third year of life that raised the risk 3.8 times, (3) positive family history of epilepsy 7.3 times, and (4) multiple episodes of FS about 10 times. Focality at the first and the second FS recurrence increased the risk of epilepsy about 9.7 and 11.7 times, respectively. Focality was the only factor that continued to be significant in further FS recurrences. A prognostic profile of each child with FS would be very useful for the follow‐up of these children.

1 May 2016 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
EPEfterpi Pavlidou Pavlidou
Efterpi Pavlidou Pavlidou
VSVincenzo Salpietro
Vincenzo Salpietro
RPRahul Phadke
Rahul Phadke
IHIain P. Hargreaves
Iain P. Hargreaves
LBLeigh Batten
Leigh Batten
MKMaria Kinali
Maria Kinali

1 October 2016 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Closed access
PDF file
EPEfterpi Pavlidou Pavlidou
Efterpi Pavlidou Pavlidou
EPEvangelos Pavlou
Evangelos Pavlou
AAAthanasia Anastasiou
Athanasia Anastasiou
ZPZoi Pana
Zoi Pana
VTVasiliki Tsotoulidou
Vasiliki Tsotoulidou
EHEmmanuel Hatzipantelis
Emmanuel Hatzipantelis
Posterior reversible encephalopathy syndrome (PRES) is a rare clinical-radiological entity characterised by seizures, severe headache, mental status instability and visual disturbances. Hypertension is typically present. We report a case of a 13-year old boy with Burkitt lymphoma/leukaemia, who presented with posterior leukoencephalopathy 24 hours after intrathecal methotrexate (MTX) infusion. The child presented with headache, seizures, elevated blood pressure and gradual deterioration of his neurological status. Midazolam, dexamethazone and furosemide were initiated leading to reduction of cerebral oedema and clinical improvement. A thorough literature review is discussed in this report. Pathophysiology of leukoencephalopathy remains unclear. It develops within 5–14 days after intrathecal MTX and resolves within a week usually without permanent neurological sequelae. Broad use of MRI has led to an increasing number of identified cases of PRES. Treatment approach is mainly to manage the underlying cause of PRES. Prognosis is generally benign; however delayed diagnosis and improper management may result in permanent brain insult.

30 May 2019 in Journal of Genetics
Verified
Journal Article
Closed access
PDF file
VVVictoria Vlachou
Victoria Vlachou
LLLine Larsen
Line Larsen
EPEfterpi Pavlidou Pavlidou
Efterpi Pavlidou Pavlidou
NINaila Ismayilova
Naila Ismayilova
NMN. D. Mazarakis
N. D. Mazarakis
MKMaria Kinali
Maria Kinali

16 December 2024 in Children
Verified
Journal Article
Open access
PDF file
Soultana PapadopoulouSoultana Papadopoulou
Soultana Papadopoulou
AAAreti Anagnostopoulou
Areti Anagnostopoulou
Dimitra V. KatsarouDimitra V. Katsarou
Dimitra V. Katsarou
Kalliopi MegariKalliopi Megari
Kalliopi Megari
Efthymia EfthymiouEfthymia Efthymiou
Efthymia Efthymiou
Eugenia I TokiEugenia I Toki
Eugenia I Toki
Background: A specific deletion on the short arm of chromosome 5 (5p) is the hallmark of the rare genetic syndrome called Cri du Chat Syndrome (CdCS). It causes severe difficulty with swallowing, speech, motor skills, and cognitive deficiencies. These arise from characteristic laryngeal abnormalities and oral–motor dysfunctions. Objective: This study aims to investigate the effectiveness of speech and language intervention in addressing the multifaceted challenges of CdCS, including speech and language impairments, feeding difficulties, and social communication deficits. Methods: A narrative review was conducted to synthesize existing studies from the last 35 years on therapeutic interventions for individuals with CdCS. This review focused on interventions targeting speech, language, and swallowing therapy. Comprehensive searches were performed in the PubMed and Scopus databases using descriptors such as “Cri du Chat”, “swallowing disorders”, “speech disorders”, “speech and language disorders”, and “speech and language therapy.” From the identified records, 40 peer-reviewed English-language publications that addressed speech, language, and swallowing interventions were selected based on relevance and inclusion criteria. Data extraction was performed independently by four reviewers, working in two teams. Any disagreements between the teams were resolved through discussion with an independent researcher to ensure reliability and minimize bias. Results: The findings demonstrate that speech and language therapy (SLT) significantly enhances speech clarity, articulation, and oral–motor coordination. Augmentative communication systems effectively bridge gaps in nonverbal communication, fostering improved social interaction. Specific interventions reduce aspiration risks and improve feeding safety, enhancing the overall quality of life. Early multidisciplinary approaches and tailored therapeutic strategies are key to maximizing the benefits of SLT. Conclusions: SLT is crucial for improving communication, swallowing, and social integration in individuals with CdCS. Regular early intervention involving individualized programs and family participation is recommended to achieve optimal outcomes. Further research is needed to evaluate long-term effects and develop cultural and technologically adaptable therapies.

9 March 2022 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
AFAngelisa Frasca
Angelisa Frasca
EPEfterpi Pavlidou Pavlidou
Efterpi Pavlidou Pavlidou
MBMatteo Bizzotto
Matteo Bizzotto
YGYunan Gao
Yunan Gao
Dario BalestraDario Balestra
Dario Balestra
MKMaria Kinali
Maria Kinali
Background and Objectives CDKL5 deficiency disorder (CDD) is a neurodevelopmental encephalopathy characterized by early-onset epilepsy and impaired psychomotor development. Variations in the X-linked CDKL5 gene coding for a kinase cause CDD. Molecular genetics has proved that almost all pathogenic missense substitutions localize in the N-terminal catalytic domain, therefore underlining the importance for brain development and functioning of the kinase activity. CDKL5 also features a long C-terminal domain that acts as negative regulator of the enzymatic activity and modulates its subcellular distribution. CDD is generally attributed to loss-of-function variations, whereas the clinical consequences of increased CDKL5 activity remain uncertain. We have identified a female patient characterized by mild epilepsy and neurologic symptoms, harboring a novel c.2873C>G nucleotide substitution, leading to the missense variant p.(Thr958Arg). To increase our comprehension of genetic variants in CDKL5-associated neurologic disorders, we have characterized the molecular consequences of the identified substitution. Methods MRI and video EEG telemetry were used to describe brain activity and capture seizure. The Bayley III test was used to evaluate the patient development. Reverse transcriptase PCR was used to analyze whether the identified nucleotide variant affects messenger RNA stability and/or splicing. The X chromosome inactivation pattern was analyzed determining the DNA methylation status of the androgen receptor (AR) gene and by sequencing of expressed alleles. Western blotting was used to investigate whether the novel Thr958Arg substitution affects the stability and/or enzymatic activity of CDKL5. Immunofluorescence was used to define whether CDKL5 subcellular distribution is affected by the Thr958Arg substitution. Results Our data suggested that the proband tends toward a skewed X chromosome inactivation pattern in favor of the novel variant. The molecular investigation revealed that the p.(Thr958Arg) substitution leads to a significant increase in the autophosphorylation of both the TEY motif and residue Tyr171 of CDKL5, as well as in the phosphorylation of the target protein MAP1S, indicating an hyperactivation of CDKL5. This occurs without evidently affecting the kinase subcellular distribution. Discussion Our data provide a strong indication that the c.2873C>G nucleotide substitution represents an hypermorphic pathogenic variation of CDKL5, therefore highlighting the importance of a tight control of CDKL5 activity in the brain.